Shield Therapeutics plc (AIM:STX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 49.86M -37.8% |
| Revenue (ttm) | 44.19M +41.3% |
| Net Income | -7.82M |
| EPS | -0.01 |
| Shares Out | 1.07B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,586,087 |
| Open | 4.826 |
| Previous Close | 4.896 |
| Day's Range | 4.600 - 5.000 |
| 52-Week Range | 3.700 - 12.500 |
| Beta | 1.77 |
| Analysts | Strong Buy |
| Price Target | 16.67 (+257.73%) |
| Earnings Date | Sep 16, 2026 |
About Shield Therapeutics
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom. [Read more]
Full Company ProfileFinancial Performance
In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for STX stock is "Strong Buy." The 12-month stock price target is 17p, which is an increase of 257.73% from the latest price.
News
Shield Therapeutics Transcript: Status update
Full U.S. commercial control of ACCRUFER is expected to nearly double EBIT and expand gross margins to 75%-80%, with no upfront payment and immediate accretion. The integrated sales force and platform support future product additions and continued growth.
Shield Therapeutics Press release: Status update
Shield Therapeutics issued a press release on September 1, 2026, disclosing material business information to investors.
Shield Therapeutics Quarterly report: H1 2026
Shield Therapeutics has published its H1 2026 quarterly earnings report on August 20, 2026.
Shield Therapeutics Earnings Call Transcript: Q2 2026
Q2 sales grew 4% sequentially but fell 20% year-over-year due to New York Medicaid changes, prompting a successful pivot to the commercial segment, which saw strong prescription and prescriber growth. H1 revenue rose 41% year-over-year, and profitability was achieved.
Shield Therapeutics Earnings release: Q2 2026
Shield Therapeutics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Shield Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw $18.4M in revenue, 44% prescription growth, and EBIT profitability, aided by a $7.9M China milestone. U.S. commercial sales drive growth, while Medicaid faces new prior authorization hurdles. Focus remains on expanding Accrufer, global markets, and acquiring a second product.
Shield Therapeutics Earnings release: Q1 2026
Shield Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Shield Therapeutics Earnings release: Trading update
Shield Therapeutics released its earnings on May 1, 2026, summarizing the period's financial results.
Shield Therapeutics Annual report: H2 2025
Shield Therapeutics has published its H2 2025 annual report on April 9, 2026.
Shield Therapeutics Annual report: H2 2025
Shield Therapeutics has published its H2 2025 annual report on April 9, 2026.
Shield Therapeutics Earnings Call Transcript: Q4 2025
Cash flow positive in Q4 2025, with 56% U.S. revenue growth and ACCRUFeR leading the branded oral iron market. 2026 guidance targets EBIT profitability, continued prescription growth, and global expansion, while actively seeking a second product for the portfolio.
Shield Therapeutics Earnings release: Q4 2025
Shield Therapeutics released its Q4 2025 earnings on January 22, 2026, summarizing the period's financial results.
Shield Therapeutics Slides: Q4 2025
Shield Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 22, 2026.
Shield Therapeutics Transcript: Trading Update
Q3 2025 saw strong revenue and prescription growth for Accrufer, with robust digital and sales force strategies driving market expansion. Cash flow positivity is expected by Q4 2025, and ex-U.S. growth continues with new launches and regulatory progress. Influencer marketing and targeted outreach are delivering measurable results.
Shield Therapeutics Earnings release: Trading Update
Shield Therapeutics released its earnings on October 23, 2025, summarizing the period's financial results.
OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX
NEW YORK, May 17, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics PLC (LSE: STXS; OT...